Læknablaðið - 15.03.2013, Síða 30

Y F I R L I T
lungum en í íslenskri rannsókn voru 21,6% sjúklinga með mein-
vörp við greiningu og voru 13,4% með meinvörp í aftanskinueitl-
um og 7,3% með fjarmeinvörp.60 Eistnakrabbamein svarar mjög vel
krabbameinslyfjum jafnvel þótt fjarmeinvörp séu til staðar.61 Horf-
ur þessara sjúklinga eru því yfirleitt ágætar en hér á landi læknast
yfir 95% sjúklinga af sjúkdómnum.60
Meðferð eistnakrabbameins felst í blöndu krabbameinslyfja
sem innihalda meðal annars cisplatín en í allt að 30% tilfella næst
ekki að lækna meinið með þeim. Ef lungnameinvörp sjást á TS
eftir lyfjameðferð getur skurðaðgerð komið til greina.61 í íslenskri
rannsókn reyndust 8 af 97 sjúklingum vera með lungnameinvörp
við greiningu og voru þeir allir með eistnakrabbamein önnur
en sáðfrumukrabbamein.60 Aðeins einn þessara sjúklinga gekkst
undir lungnaaðgerð og læknaðist hann af sjúkdómnum.6 í nýlegri
samantekt á 6 rannsóknum sem tóku til 407 sjúklinga sem gengist
höfðu undir brottnám á lungnameinvörpum frá einstnakrabba-
meini öðru en sáðfrumukrabbameini var dánarhlutfall innan 30
daga undir 4% og 5 ára lifun á bilinu 73-94%.61 Rannsóknir hafa
einnig sýnt betri lifun þegar fjöldi meinvarpa er undir fjórum62 og
þegar hækkun á æxlisvísunum alfa fetoprotein og beta human chorio-
nic gonadotropin (b-HCG ) er lítil.61
Lokaorð
Þegar meinvörp eru bundin við lungu getur brottnám með skurð-
aðgerð komið til greina. Þetta á sérstaklega við um sjúklinga með
stök/fá meinvörp frá sarkmeini, ristil- og endaþarmskrabbameini
og nýrnafrumukrabbameini. Ekki eru til framskyggnar, slembaðar
rannsóknir á árangri þessara aðgerða en fjöldi afturskyggnra rann-
sókna hefur sýnt að lifun þeirra sem gangast undir aðgerð er betri
en eftir aðra meðferð. Þó er mikilvægt að hafa í huga að sjúklingar
sem gangast undir aðgerð eru valinn hópur og valskekkja getur því
haft áhrif á niðurstöður samanburðarrannsókna, skurðaðgerðum í
hag. Engu að síður er ljóst að brottnám lungnameinvarpa er örugg
aðgerð þar sem tíðni fylgikvilla er lág og innan við 1% sjúklinga
lifa ekki af aðgerðina. Mikih'ægt er að vanda val á sjúklingum í
aðgerð en til þess eru sameiginlegir krabbameinsfundir tilvaldir.
í dag eru slíkir fundir haldnir innan flestra sérgreina hér á landi.
Heimildir
1. Hornbech K, Ravn J, Steinbruchel DA. Current status of
pulmonary metastasectomy. Eur J Cardiothorac Surg 2011;
39: 955-62.
2. Alexander J, Haight C. Pulmonary resection for solitary
metastatic sarcomas and carcinomas. Surg Gynecol Obstet
1947,85:129-46.
3. Thomford NR, Woolner LB, Clagett OT. The Surgical
Treatment of Metastatic Tumors in the Lungs. J Thorac
Cardiovasc Surg 1965; 49: 357-63.
4. Hoetzenecker K, Lang G, Ankersmit HJ, Klepetko W.
Pulmonary metastasectomy. European surgery 2011.
5. Rusch VW. Pulmonary metastasectomy: a moving target. J
Thorac Oncol 2010; 5: S130-131.
6. Vidarsdottir H, Moller PH, Jonasson JG, Pfannschmidt
J, Gudbjartsson T. Indications and surgical outcome fol-
lowing pulmonary metastasectomy: a nationwide study.
Thorac Cardiovasc Surg 2012; 60: 383-9.
7. Diederich S, Semik M, Lentschig MG, Winter F, Scheld
HH, Roos N, et al. Helical CT of pulmonary nodules
in patients with extrathoracic malignancy: CT-surgical
correlation. AJR Am J Roentgenol 1999; 172: 353-60.
8. Detterbeck FC, Grodzki T, Gleeson F, Robert JH. Imaging
requirements in the practice of pulmonary metastasec-
tomy. J Thorac Oncol 2010; 5: S134-139.
9. Pastorino U, Veronesi G, Landoni C, Leon M, Picchio M,
Solli PG, et al. Fluorodeoxyglucose positron emission
tomography improves preoperative staging of resectable
lung metastasis. J Thorac Cardiovasc Surg 2003,126:1906-
10.
10. Fortes DL, Allen MS, Lowe VJ, Shen KH, Wigle DA, Cassivi
SD, et al. The sensitivity of 18F-fluorodeoxyglucose posi-
tron emission tomography in the evaluation of metastatic
pulmonary nodules. Eur J Cardiothorac Surg 2008; 34:
1223-7.
11. Dalrymple-Hay MJ, Rome PD, Kennedy C, Fulham
M, McCaughan BC. Pulmonary metastatic melanoma
-- the survival benefit associated with positron emission
tomography scanning. Eur J Cardiothorac Surg 2002; 21:
611-4; discussion 614-5.
12. Colice GL, Shafazand S, Griffin JP, Keenan R, Bolliger CT.
Physiologic evaluation of the patient with lung cancer
being considered for resectional surgery: ACCP eviden-
ced-based clinical practice guidelines (2nd edition). Chest
2007; 132:161S-177S.
13. Garcia-Yuste M, Cassivi S, Paleru C. Thoradc lymphatic
involvement in patients having pulmonary metastasec-
tomy: incidence and the effect on prognosis. J Thorac
Oncol 2010; 5: S166-169.
14. Pfannschmidt J, Klode J, Muley T, Dienemann H,
Hoffmann H. Nodal involvement at the time of pulmon-
ary metastasectomy: experiences in 245 patients. Ann
Thorac Surg 2006; 81:448-54.
15. Veronesi G, Petrella F, Leo F, Solli P, Maissoneuve P,
Galetta D, et al. Prognostic role of lymph node involve-
ment in lung metastasectomy. J Thorac Cardiovasc Surg
2007; 133:967-72.
16. Okumura S, Kondo H, Tsuboi M, Nakayama H, Asamura
H, Tsuchiya R, et al. Pulmonary resection for metastatic
colorectal cancer: experiences with 159 patients. J Thorac
Cardiovasc Surg 1996; 112: 867-74.
17. Long-term results of lung metastasectomy: prognostic
analyses based on 5206 cases. The Intemational Registry
of Lung Metastases. J Thorac Cardiovasc Surg 1997; 113:
37-49.
18. Hornbech K, Ravn J, Steinbruchel DA. Outcome after pul-
monary metastasectomy: analysis of 5 years consecutive
surgical resections 2002-2006. J Thorac Oncol 2011; 6:1733-
40.
19. Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer
C, Dienemann H. Prognostic factors for survival after
pulmonary resection of metastatic renal cell carcinoma.
Ann Thorac Surg 2002; 74:1653-7.
20. Migliore M, Jakovic R, Hensens A, Klepetko W. Extending
surgery for pulmonary metastasectomy: what are the
limits? J Thorac Oncol 2010; 5:S155-160.
21. Koong HN, Pastorino U, Ginsberg RJ. Is there a role for
pneumonectomy in pulmonary etastases? Intemational
Registry of Lung Metastases. Ann Thorac Surg 1999; 68:
2039-43.
22. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical
resection of pulmonary metastases from colorecta! cancer:
a systematic review of published series. Ann Thorac Surg
2007; 84: 324-38.
23. Kim S, Ott HC, Wright CD, Wain JC, Morse C, Gaissert
HA, et al. Pulmonary resection of metastatic sarcoma:
prognostic factors associated with improved outcomes.
Ann Thorac Surg 2011; 92:1780-6; discussion 1786-7.
24. Molnar TF, Gebitekin C, Turna A. What are the considera-
tions in the surgical approach in pulmonary metastasec-
tomy? J Thorac Oncol 2010; 5: S140-144.
25. Carballo M, Maish MS, Jaroszewski DE, Holmes CE.
Video-assisted thoracic surgery (VATS) as a safe altema-
tive for the resection of pulmonary metastases: a retro-
spective cohort study. J Cardiothorac Surg 2009; 4:13.
26. Cerfolio RJ, Bryant AS, McCarty TP, Minnich DJ. A pro-
spective study to determine the incidence of non-imaged
malignant pulmonary nodules in patients who undergo
metastasectomy by thoracotomy with lung palpation. Ann
Thorac Surg 2011; 91:1696-701.
27. Cerfolio RJ, McCarty T, Bryant AS. Non-imaged pulmon-
ary nodules discovered during thoracotomy for metasta-
sectomy by lung palpation. Eur J Cardiothorac Surg 2009;
35: 786-91; discussion 791.
28. Welter S, Jacobs J, Krbek T, Krebs B, Stamatis G. Long-term
survival after repeated resection of pulmonary metastases
from colorectal cancer. Ann Thorac Surg 2007; 84: 203-10.
29. Pfannschmidt J, Muley T, Hoffmann H, Dienemann H.
Prognostic factors and survival after complete resection
of pulmonary metastases from colorectal carcinoma:
experiences in 167 patients. J Thorac Cardiovasc Surg
2003; 126: 732-9.
30. Venuta F, Rolle A, Anile M, Martucci N, Bis B, Rocco G.
Techniques used in lung metastasectomy. J Thorac Oncol
2010; 5: S145-150.
31. Steinke K, Glenn D, King J, Clark W, Zhao J, Clingan P, et
al. Percutaneous imaging-guided radiofrequency ablation
in patients with colorectal pulmonary metastases: 1-year
follow-up. Ann Surg Oncol 2004; 11: 207-12.
32. Siva S, MacManus M, Ball D. Stereotactic radiotherapy for
pulmonary oligometastases: a systematic review. J Thorac
Oncol 2010; 5:1091-9.
33. Snaebjomsson P, Jonasson L, Jonsson T, Moller PH,
Theodors A, Jonasson JG. Colon cancer in Iceland-a
nationwide comparative study on various pathology
parameters with respect to right and left tumor location
and patients age. Int J Cancer 2010; 127: 2645-53.
34. Pfannschmidt J, Hoffmann H, Dienemann H. Reported
outcome factors for pulmonary resection in metastatic
colorectal cancer. J Thorac Oncol 2010; 5: S172-178.
35. Headrick JR, Miller DL, Nagomey DM, Allen MS,
Deschamps C, Trastek VF, et al. Surgical treatment of
hepatic and pulmonary metastases from colon cancer. Ann
Thorac Surg 2001; 71: 975-9; discussion 979-80.
36. Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs
CS, Ramanathan RK, et al. Five-year data and prognostic
factor analysis of oxaliplatin and irinotecan combinations
for advanced colorectal cancer: N9741. J Clin Oncol 2008;
26: 5721-7.
37. Kanemitsu Y, Kato T, Hirai T, Yasui K. Preoperative
probability model for predicting overall survival after
resection of pulmonary metastases from colorectal cancer.
BrJSurg 2004; 91:112-20.
38. Krabbamein á íslandi - Upplýsingar úr Krabbameinsskrá
fyrir tímabilið 1957-2006. Ritstj. Jónasson JG.
Krabbameinsfélagið, Reykjavík 2008.
39. Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE.
Prognostic factors and survival after pulmonary resection
of metastatic renal cell carcinoma. Eur Urol 2005; 48:77-81;
discussion 81-2.
142 LÆKNAblaöið 2013/99